Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: ok1day who wrote (52192)	2/29/2000 5:11:00 PM
From: Jim Spitz	Respond to of 122089

type VASO in the quotes window and then click on quotes. Then click news link - third, click on today's news and read. Stay in the Black! jimS

To: ok1day who wrote (52192)	2/29/2000 5:28:00 PM
From: Tassi	Respond to of 122089

MAYO CLINIC PHYSICIANS CONFIRM POSITIVE EARLY RESULTS WITH ENHANCED EXTERNAL COUNTERPULSATION BUSINESS EDITORS WESTBURY, NY--(BUSINESS WIRE)--FEB. 29, 2000--VASOMEDICAL, INC. (NASDAQ:VASO) ANNOUNCED -------------------------------------------------------------------------------- WESTBURY, NY--(BUSINESS WIRE)--Feb. 29, 2000--Vasomedical, Inc. (Nasdaq:VASO.O) announced today that the Mayo Clinic, one of the most respected medical facilities in the world, has reported further on initial results with enhanced external counterpulsation (EECP(R)) therapy. Their positive experience was recently published as an interview in the Rochester Post-Bulletin and confirms several case studies reported at the AHA in November. Gregory Barsness, M.D., Medical Director for the EECP therapy program at Mayo reported, "Of the 21 patients who've tried the therapy since Mayo started using it a year ago, 20 of them have had positive results, some have improved dramatically. We are cautiously optimistic about the therapy, ...we have had dramatic responses, so we're enthusiastic and we're actively pursuing it." EECP therapy is a noninvasive outpatient treatment for the angina (chest pain) which often accompanies coronary artery disease. The therapy, which is covered by Medicare, is relatively new to the Mayo Clinic, but is in use at over 100 centers across the country. Dr. Barsness further indicated that Mayo and other medical centers are studying EECP therapy to determine why the treatment works in so many patients. He pointed out that heart disease is a leading killer of both men and women; many heart disease patients do not qualify for common treatment methods and EECP therapy could turn out to be a big help for these patients. Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting external counterpulsation systems based on the company's proprietary technology. EECP(R) is a registered trademark for Vasomedical's enhanced external counterpulsation system. This system is now in use at major medical centers, including the Mayo Clinic, the Ochsner Foundation Hospital and the Miami Heart Institute, as well as medical centers affiliated with Columbia University, the University of Pittsburgh, the University of California San Diego, the University of California San Francisco, and the University of Virginia. The company provides hospitals, clinics and private practices EECP(R) equipment, treatment guidance and a staff training and maintenance program to ensure optimal patient outcomes. Except for historical information contained in this release, the matters discussed are forward looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believe," "estimate," "expect" and "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments. --30--es/ny* CONTACT: Anthony Peacock VP Clinical Affairs 516/997-4600 Ext. 120 or Jeanette Hutter MediaMedica, Inc. 215/402-9175 eecp.com/news KEYWORD: NEW YORK INDUSTRY KEYWORD: MEDICAL DEVICES BIOTECHNOLOGY Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Copyright 2000, Business Wire